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Microscopic polyangiitis secondary to
Mycobacterium abscessus in a patient
with bronchiectasis: a case report
C. Addy1,2* , G. Doran2, A. L. Jones3, G. Wright4, S. Caskey2 and D. G. Downey1,2
Abstract
Background: Non-Tuberculous Mycobacterial–pulmonary disease (NTM-PD) is increasing in incidence and
prevalence. Mycobacterium abscessus (M.abscessus) is a rapid growing multi-resistant NTM associated with
severe NTM-PD requiring prolonged antibiotic therapy. Complications of therapy are common but reports on
direct complications of active NTM-PD are rare. Vasculitis has been described as a rare complication of NTM-
PD, most often in individuals with inherited immune defects. This case is the first to describe an ANCA positive
vasculitide (Microscopic Polyangiitis) secondary to M.abscessus pulmonary disease.
Case presentation: A 70 year old female with bronchiectasis underwent a clinical decline associated with the growth
of M.abscessus and was diagnosed with NTM-PD. Before treatment could be initiated she developed small joint arthralgia
and a glove and stocking axonal loss sensorimotor neuropathy. Positive Perinuclear Anti-Neutrophil Cytoplasmic
Antibodies (P-ANCA) and Myeloperoxidase-ANCA (MPO-ANCA) titres led to a diagnosis of microscopic polyangiitis.
Further investigation revealed reduced interferon-gamma production but no other significant immune dysfunction.
Dual treatment with immunosuppressive therapy (Corticosteroids/Cyclophosphamide) for vasculitis and antimicrobial
therapy for M.abscessus NTM-PD was initiated. Clinical stability was difficult to achieve with reductions in
immunosuppression triggering vasculitic flares. One flare led to retinal vein occlusion with impending visual
loss requiring escalation in immunosuppression to Rituximab infusions. An increase in immunosuppression led
to a deterioration in NTM-PD necessitating alterations to antibiotic regimes. Adverse effects including alopecia
and Achilles tendonitis have further limited antibiotic choices resulting in a strategy of pulsed intra-venous
therapy to stabilise NTM-PD.
Conclusions: This is the first reported case of an ANCA positive vasculitis secondary to M.abscessus pulmonary disease.
This rare but important complication had a significant impact on the patient adding to the complexity of an already
significant disease and treatment burden. The potential role of reduced interferon-gamma production in this case
highlights the importance of investigating immune function in those with mycobacterial infection and the intricate
relationship between mycobacterial infection and immune dysfunction. Immune dysfunction caused by genetic
defects or immunosuppressive therapy is a known risk factor for NTM-PD. Balancing immunosuppressive therapy with
prolonged antimicrobial treatment is challenging and likely to become more common as the number of individuals
being treated with biologics and immunosuppressive agents increases.
Keywords: Non-tuberculous mycobacteria, Non-tuberculous mycobacterial pulmonary disease Mycobacterium
abscessus, Vasculitis, Interferon-gamma, Bronchiectasis
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Background
The incidence and prevalence of Non-Tuberculous
Mycobacterial–pulmonary disease (NTM-PD) is increas-
ing [1, 2]. Understanding the spectrum of disease and
pathogenicity of differing Non-Tuberculous Mycobac-
teria (NTM) has advanced in line with developments in
microbiological detection highlighting the need to
sub-speciate NTM and alter management accordingly
[1]. NTM can cause progressive lung disease or reside
within the lungs asymptomatically [1]. Treatment regi-
mens are prolonged, toxic and difficult to tolerate. Deci-
sions to commence treatment are based on a number of
factors including disease severity, frequency of positive
cultures, progression of radiological appearances, under-
lying lung disease, co-morbidities and pathogenicity of
individual species [1].
Guidance on treating NTM-PD was first published in
2007 [3] with no further guidance published until the
2016 Cystic Fibrosis specific consensus document [4]
and 2017 British Thoracic Society guidelines [5]. This is
due to lack of evidence in this area and to the complex-
ity of the disease. Increasing incidence and prevalence of
NTM-PD highlights the need for further research and
guidance [1].
Mycobacterium abscessus (M.abscessus) is one of the
most pathogenic NTMs, particularly in those with
underlying lung disease [5]. It is a multi-resistant organ-
ism with limited antibiotic options and is challenging to
treat [5]. M. abscessus is a rapid growing NTM which
can be sub-speciated into M.a.abscessus, M.a.massiliense
and M.a.bolletii [5]. The initial treatment aim is eradica-
tion, which commonly fails and therefore long-term
chronic suppressive therapy becomes necessary. Devel-
opment of macrolide resistance is associated with re-
duced rates of culture conversion and increased chronic
infection [5]. Evidence on optimal antibiotic regimes and
longer-term outcomes of chronic suppressive treatment
are limited [3, 5]. Those with the subspecies M.a.absces-
sus have much lower rates of culture conversion [5]. The
impact of M.abscessus infection on patients should not
be underestimated because of prolonged toxic treatment
regimens that it requires, the need for stringent infection
control precautions and it’s relative contra-indication to
lung transplantation [4, 5].
Case presentation
A 70-year-old female had been symptomatic with a per-
sistent non-productive cough and recurrent chest infec-
tions for 10 years. At presentation to clinic a CT thorax
showed right middle lobe bronchiectasis. She was a
life-long non-smoker with no childhood history of re-
spiratory disease and normal baseline investigations for
immune deficiency. Clinical stability was achieved with
long term Azithromycin and regular airway clearance.
Staphyloccocus aureus (S.aureus) was cultured intermit-
tently from sputum samples with repeatedly negative
mycobacterial cultures. A repeat CT 6 years after her ini-
tial scan demonstrated progression of disease with
bi-apical scarring, right middle lobe atelectasis, right
upper lobe cylindrical bronchiectasis and reticulo-nodular
densities in both lower lobes. (Fig. 1) Nebulised Tobra-
mycin was trialled to suppress S.aureus and stabilise
radiological appearances but stopped after 15 months due
to worsening cough.
M. abscessus was first isolated from her sputum in No-
vember 2013; sub-speciated into M.a. abscessus. Com-
mencement of therapy was under consideration when, 3
months from first isolation of M.abscessus, paraesthesia
developed in her hands and feet with associated small
joint arthropathy. A subtle purpuric rash was evident on
the lower limbs. Nerve conduction studies confirmed an
axonal loss sensorimotor neuropathy. Erythrocyte Sedi-
mentation Ratio was elevated at 49 mm/hr, Perinuclear
Anti-Neutrophil Cytoplasmic Antibodies (P-ANCA) titre
was highly positive at 80 AI and Myeloperoxidase-
ANCA (MPO-ANCA) was > 8 AI with Proteinase-3–
ANCA (PR3-ANCA) < 0.2 AI. Renal function and urine
microscopy were normal. A diagnosis of microscopic po-
lyangiitis was made. Treatment with Cyclophosphamide
and high dose Prednisolone was commenced with full
resolution of her paraesthesia.
Within 4 months of first isolation, all sputum samples
(n = 4) were culture positive and 66% of those samples
were smear positive for M. abscessus. C-Reactive Protein
was elevated at 86.2 mg/l. A repeat CT thorax showed
extensive bronchiectasis with underlying collapse in the
right upper and lower lobes. There was extensive
tree-in-bud change within the right lower lobe, scattered
pulmonary nodules and small areas of ground glass sha-
dowing in both lungs. Deteriorating radiological appear-
ances and commencement of active immunosuppression
prompted urgent initiation of M. abscessus treatment.
Treatment
Induction phase treatment comprised intravenous (IV)
Cefoxitin and Amikacin with oral Clarithromycin and
Minocycline and was tolerated for 2 weeks. Long-term
nebulised Amikacin was commenced, along with oral
Moxifloxacin, Minocycline and Clarithromycin.
A month later she attended the Emergency Depart-
ment (ED) with rupture of her right Achilles tendon sec-
ondary to Moxifloxacin. This was stopped immediately
and replaced with Linezolid. Despite dose reduction this
was discontinued due to intolerable nausea, diarrhoea
and angular stomatitis. She remained on oral Minocy-
cline, Clarithromycin and nebulised Amikacin. Cyclo-
phosphamide was changed to Azathioprine as long-term
immunosuppression, but this was poorly tolerated due
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to nausea. Significant alopecia then developed; attributed
to Minocycline, which was also discontinued. Nebulised
Meropenem was therefore added to maintain triple anti-
biotic therapy.
On review 17 months after initiation of treatment her
pulmonary disease appeared more stable. A regime of
nebulised Meropenem, nebulised Amikacin and oral
Clarithromycin was tolerated. Smear and culture nega-
tivity was maintained for a further 12 months on this re-
gime. P-ANCA and MPO-ANCA titres remained within
normal limits during this period.
Twenty months after starting treatment, cultures again
became positive for M.abscessus. A month after culture
positivity returned, she presented to the ED with visual
loss secondary to a right branch retinal vein occlusion.
MPO-ANCA had again become highly positive at > 8 AI
and P-ANCA titre was 160 AI. Due to active vasculitis
with impending visual loss from associated hyperco-
agulability and thromboembolism higher dose im-
munosuppression was required. She commenced
Rituximab and Methylprednisolone infusions weekly
for 4 weeks, followed by 6 monthly Rituximab. Clin-
ical response was achieved with CD19 count redu-
cing from 46% to 0%. Within the following
12 months sputum samples became smear positive
again. High resolution CT chest demonstrated exten-
sive airspace opacification, ill-defined nodularity and
tree in bud change. (Fig. 2)
Outcome and follow-up
Further assessment of immunological function was car-
ried out, including vaccination response, respiratory oxi-
dative burst, Mannan Binding Lectin, IgG subsets,
complement levels, alternative and innate signalling
pathways. Specific testing of interferon pathways demon-
strated a very low interferon-gamma (IFN-γ) level, with
low production of Interleukin-17 (IL-17) but no auto-
antibodies to IFN-γ.
No other organisms, including S.aureus have been de-
tected by standard sputum culture since 2012. Four
years from first isolation she remained M.abscessus
smear and culture positive. Clarithromycin resistance
was now detectable necessitating its cessation. A further
3 weeks of IV Amikacin, Cefoxitin and Tigecycline was
commenced. Long-term treatment continued with nebu-
lised Meropenem and Amikacin.
A third oral agent would optimise long-term therapy
but intolerances, resistance and risk of visual loss pre-
vent the use of almost all suitable oral agents. Clofazi-
mine was not commenced due to risk of further visual
loss. A trial of oral Co-trimoxazole [5] resulted in
intolerable nausea and had to be stopped. As no third
oral agent could be used, pulsed IV antibiotics have been
introduced. The optimal duration between IV courses is
unknown and is currently based on recurrence of smear
positivity or deteriorating symptoms. The first repeat IV
antibiotic course maintained smear negativity for
Fig. 1 CT Thorax 2007: CT Thorax from 2007 demonstrating bi-apical scarring, right middle lobe atelectasis, right upper lobe cylindrical bronchiectasis
and reticulo-nodular densities in both lower lobes
Fig. 2 CT Thorax 2016: High resolution CT Chest from 2016 demonstrating extensive airspace opacification, ill-defined nodularity and tree
in bud change
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6 months. Recurrence of smear positivity and associated
clinical deterioration have required further IV courses
(Table 1).
Discussion
This case highlights a rare systemic complication of
NTM-PD and is the first reported case of ANCA-posi-
tive vasculitis as a consequence of M. abscessus infec-
tion. It demonstrates the complexity of managing
NTM-PD including therapeutic challenges and the rela-
tionship between immune function and NTM infection.
NTM-PD is increasing in incidence and prevalence.
Determining the clinical relevance of NTM isolates can
be difficult [2]. M. abscessus is the 3rd most commonly
isolated NTM in the USA [5]. It predominantly affects
white, female non-smokers over the age of 60 [5]. It can
occur in the absence of underlying lung disease where
the course can be slow and indolent. In the setting of
pre-existing lung disease such as CF or bronchiectasis, it
can be fulminant and rapidly progressive [5]. The radio-
graphic picture is of inflammatory nodules, tree-in-bud
opacities and cavitation particularly in areas of under-
lying bronchiectasis [4].
There is wide variation in how patients with M.
abscessus NTM-PD are treated [4]. An intensive induc-
tion phase consisting of three IV antibiotics adminis-
tered for several weeks in combination with an oral
agent is common [4, 5]. This is usually followed by at
least two oral antimicrobials in addition to a macrolide
antibiotic and inhaled antibiotic(s) [4]. Side effects of
antimicrobial therapy are significant and can limit treat-
ment options over a prolonged treatment period. In one
study 65% patients stopped at least one antibiotic due to
adverse events or toxicity [6]. In this case the additive
toxicity of both anti-microbial and immunosuppressive
agents further increased the side effect profile (Table 2).
The association between vasculitis and chronic sup-
purative lung conditions [7, 8] is thought to result from
excessive humoral immune responses secondary to cir-
culating immune complexes [8]. Pulmonary infection
may trigger vasculitis through induction of ANCA anti-
gen expression on the surface of neutrophils [9]. The
temporal relationship between M.abscessus growth,
ANCA positivity and vasculitic symptoms reduces the
chance of the two being unrelated, suggesting M.absces-
sus was a causative trigger for the vasculitides. S.aureus
had been chronically cultured since presentation with no
prior evidence of vasculitis reducing the likelihood of
S.aureus being a causative factor. Previous case reports
have described ANCA-positive vasculitis secondary to
M.avium complex [10]. Leukocytoclastic vasculitis linked
to Salmonella has been reported in children with genetic
Interferon-gamma deficiency [11]. Leukocytoclastic vas-
culitis in an individual with interferon-gamma
autoantibodies and disseminated M. abscessus has also
been reported [12]. Increased susceptibility to mycobac-
terial disease has been reported in genetic interferon de-
fects but a causal link with associated vasculitides has
not been established [13]. It is possible the reduction in
IFN-γ seen in this case may have contributed both to
development of vasculitis and poor treatment response.
The use of IFN-γ had been considered in this case.
IFN-γ production is integral to mycobacterial defence
through activation of both innate and adaptive immune
systems via the interleukin12-IFN-γ pathway [13, 14].
IFN-γ facilitates mycobacterial killing by enhancing
phagocytosis and expression of oxygen free radicals [14].
Administration is associated with a flu like syndrome
[15–17]. Intramuscular IFN-γ as adjuvant therapy for M.
avium complex resulted in clinical benefit over antibi-
otics alone [5, 15] but of insufficient magnitude to war-
rant recommending routine use [5]. IFN-γ therapy in
management of M. abscessus disease is limited to case
reports of use in disseminated disease [16, 18].
Rituximab has been successfully used in disseminated M.
abscessus disease refractory to antibacterial chemotherapy
in those with IFN-γ autoantibodies [12, 19]. It can restore
IFN-γ signalling in these individuals [12, 19]. Whether this
is true in those without autoantibodies, as in this case is un-
known, as is any potential interaction between Rituximab
and IFN-γ therapy. In this case monitoring Rituximab re-
sponse first was considered of lowest risk but the addition
of IFN-γ could be re-visited.
Treatment regimens for systemic vasculitis comprise
high dose induction immunosuppression followed by oral
maintenance therapy for 12–18 months [9]. The challenge
in this case was balancing adequate immunosuppression
with sufficient antimicrobial therapy to maintain clinical
stability alongside smear and culture negativity. Reduc-
tions in immunosuppression triggered vasculitic flares
with sight threatening consequences whilst increases in
immunosuppression led to a deterioration in NTM-PD.
This case highlights the complex interplay between
immune function and NTM-PD both as a complication
and a cause of disease [13, 14, 20]. Defects in IFN-γ
pathways, both acquired and genetic are associated with
NTM-PD [14, 20]; as are defects in macrophage and
dendritic cell function and cytokine signalling [5, 13].
Whole genome sequencing has demonstrated higher
rates of genetic variants in immune, Cystic Fibrosis
Transmembrane Conductance Regulator, cilial function
and connective tissue categories in people with
NTM-PD. [21] Screening for immune defects in those
with NTM-PD who fail to respond to “standard” treat-
ment is increasingly recommended [5] and may allow
better prognostication and management in the future.
Equally, those with known immune dysfunction should
be screened for NTM.
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Table 2 Adaption from RA Floto, KN Olivier, L. Saiman et al.US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus
recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax; 2016:71:i1-i22; Haworth
CS, Banks J, Capstick T et al. British Thoracic Society Guidelines for the Diagnosis and Management of Non-Tuberculous Mycobacterial
Pulmonary Disease (NTM-PD). Thorax; 2017;72:2; Lallana EC and Fadul CE. Toxicities of Immunosuppressive Treatment of Autoimmune
Neurologic Diseases. Curr Neuropharmacol. 2011 Sep; 9 (3):468–477 [24]
Drug Common Side Effects
Amikacin Nephrotoxicity,
Ototoxicity: irreversible vestibulocochlear nerve damage.
Azithromycin Nausea, Vomiting, Diarrhoea, Fulminant Hepatitis, Pseudomembranous Colitis
Ototoxicity
Prolonged QT
Clarithromycin Hepatitis
Taste Disturbance
Prolonged QT
Cefoxitin Fever, Rash
Eosinophilia, Anaemia, Leucopenia, Thrombocytopenia
Clofazimine Pink Brownish-Black Discoloration of Skin, Ichthyosis and dry skin
Enteropathy, Nausea and Vomiting
Conjunctival pigmentation, Dimness of vision and dry eyes.
Co-Trimoxazole Nausea, Vomiting, Diarrhoea
Anaemia, Leucopenia, Thrombocytopenia
Hyponatraemia, Hyperkalaemia
Fever, Rash, Steven Johnson Syndrome
Ethambutol Optic Neuritis
Hyperuricaemia
Peripheral Neuropathy
Imipenem Rash and Urticaria
Hepatitis, Nausea, Vomiting Diarrhoea
Linezolid Anaemia, Leucopenia, Thrombocytopenia
Peripheral Neuropathy
Optic Neuritis
Moxifloxacin Nausea, Vomiting, Diarrhoea
Insomnia, Agitation, Anxiety
Tendonitis
Photosensitivity
Prolonged QT
Minocycline Photosensitivity
Nausea, Vomiting, Diarrhoea, Dysphagia
Vertigo, Headache
Skin Hyperpigmentation
Rifampicin Orange discoloration of bodily fluids
Hepatitis, Nausea, Vomiting, Diarrhoea
Fever, Chills
Thrombocytopenia
Renal Failure
Increased hepatic metabolism of numerous drugs
Streptomycin Nephrotoxicity
Ototoxicity
Tigecycline Nausea, Vomiting, Diarrhoea, Pancreatitis, Bilirubinaemia
Increased risk of infections: sepsis/septic shock
Hypoproteinaemia
Corticosteroids Cataract
Increased risk of infection
Type 2 Diabetes Mellitus
Osteoporosis
Gastrointestinal bleeding
Altered Mood – rarely psychosis
Proximal myopathy
Hypertension
Cyclophosphamide Leucopenia
Haemorrhagic Cystitis
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Striking the balance between managing infection and
immunosuppression is an increasing issue in clinical
medicine with rising numbers of patients receiving bio-
logics, immunosuppressive agents and increasing life-
span post haematological and solid organ transplants [5,
22, 23]. Oral corticosteroid use is up to eight times
higher amongst cases of NTM infection [22]. Rates of
NTM-PD are five to ten fold higher in patients on
anti-TNF alpha therapies [23]. Whilst other biological
agents, carry a theoretical increased risk of NTM there
is little data on infection rates [15]. Acquisition of NTM
infection is likely due to disruption or depletion of cell
mediated immunity which is a critical component of
host defence against mycobacterium [14]. Adequate
screening of high-risk populations for NTM is necessary
to further understanding of disease rates and facilitate
appropriate intervention [1, 5, 22] (Table 3).
Conclusion
Effective treatment of NTM-PD requires effective
communication and team working between specialities
treating this complex group of patients. Balancing im-
munosuppressive with anti-microbial regimes and their
relative toxicities is challenging and requires frequent as-
sessment, monitoring and treatment adjustment. Further
research will refine management approaches and improve
our understanding of the role of innate, adaptive and
auto-immune dysfunction and the incidence of related
complications including vasculitis.
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Table 3 Key Learning points and Patient Perspective
Patient Perspective
“When I was diagnosed with bronchiectasis in my late forties, it did not
affect me day to day and I continued to work, raise my family and have
an active social life. However, since being diagnosed with
Mycobacterium Abscessus and Vasculitis, I have struggled with tiredness
and progressive shortness of breath especially when exerting myself. I
am no longer as active as I wish to be, in particular I struggle to keep
up with my toddler grand-daughter and make it around the golf course.
However, I make the effort to continue to take light exercise every day
by meeting friends for coffee, going shopping and short walks when
the weather permits.”
Learning Points
• NTM Pulmonary disease is increasing in prevalence and should be
screened for in in at risk groups. NTM-PD should also be considered if
appropriate radiological appearances and /or symptoms develop in
these groups.
• Treatment regimens are toxic and difficult to tolerate and therefore
timing of treatment and goals of treatment are important as well as
clear communication with patients in this regard
• With increases in therapies which impair immunity the rates of NTM-PD
in these groups may continue to rise
• Vasculitis triggered by NTM is a rare but significant complication of
NTM and this is the first reported case of this being due to M.Abcessus.
• Balancing effective immunosuppression with active treatment for
infection is challenging and requires specialist expertise and collaborative
working between specialist services.
Table 2 Adaption from RA Floto, KN Olivier, L. Saiman et al.US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus
recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax; 2016:71:i1-i22; Haworth
CS, Banks J, Capstick T et al. British Thoracic Society Guidelines for the Diagnosis and Management of Non-Tuberculous Mycobacterial
Pulmonary Disease (NTM-PD). Thorax; 2017;72:2; Lallana EC and Fadul CE. Toxicities of Immunosuppressive Treatment of Autoimmune
Neurologic Diseases. Curr Neuropharmacol. 2011 Sep; 9 (3):468–477 [24] (Continued)
Drug Common Side Effects
Infertility
Long term increase risk of cancer e.g. Bladder Malignancy, Myeloproliferative disorders
Nausea, Hair Loss, Skin Irritation
Azathioprine Hepatotoxicity, Pancreatitis
Leucopenia
Fatigue, Hair loss Diarrhoea
Increased risk of malignancy
Rituximab Rash
GI upset
Serious Infection, CNS toxicity
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